Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel immunostimulant combo shows early efficacy

Key clinical point: A combination of immunostimulating agents showed early efficacy against refractory cancers.

Major finding: Two of five patients with stage IV melanoma had partial responses and significant tumor shrinkage.

Study details: An ongoing, phase Ib/2 safety and dose-escalation trial.

Disclosures: The REVEAL study is supported by Nektar Therapeutics. Dr. Diab reported institutional research funding, consulting fees, and advisory board participation from Nektar, Bristol-Myers Squib, Idera Pharmaceuticals, Jounce Therapeutics, and Array BioPharma.


Diab A et al. ASCO-SITC, Abstract 26.